首页 正文

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

{{output}}
The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is discouraging with salvage standard approaches. Mutations of isocitrate dehydrogenase 1 (IDH1 mut ), present in 7-14% of AML patients, have been discovered recently, openi... ...